Pramlintide OverviewPramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca). Pramlintide is sold as an acetate salt. Contents 1 Pharmacology 2 Approval 3 Design and structure 4 References 5 External links Pharmacology Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas along ...
Read more Pramlintide Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pramlintide
Recent Pramlintide Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 0.6mg/ml, 1.5mg/1.5ml (1mg/ml), 2.7mg/2.7ml (1mg/ml), 3mg/5ml (0.6mg/ml), 3mg/5ml (600mcg/ml), 3mg/5ml (600ugm/ml)
NDC Database Records for Pramlintide: (4 results)Sorted by National Drug Code
- 0310-6615 Symlinpen 1000 ug/ml Subcutaneous Injection by Astrazeneca Pharmaceuticals Lp
- 0310-6627 Symlinpen 1000 ug/ml Subcutaneous Injection by Astrazeneca Pharmaceuticals Lp
- 66780-115 Symlinpen 1000 ug/ml Subcutaneous Injection by Amylin Pharmaceuticals, Inc.
- 66780-121 Symlinpen 1000 ug/ml Subcutaneous Injection by Amylin Pharmaceuticals, Inc.
Other drugs which contain Pramlintide or a similar ingredient: (1 result)
- SYMLIN Pramlintide